Published in J Virol on January 01, 1993
Immunogenicity of Gardasil-9 HPV Vaccine in People Living With HIV (AGO-Gard) | NCT05266898
Efficient self-assembly of human papillomavirus type 16 L1 and L1-L2 into virus-like particles. J Virol (1993) 5.12
Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc Natl Acad Sci U S A (1995) 4.15
Simultaneous quantitation of antibodies to neutralizing epitopes on virus-like particles for human papillomavirus types 6, 11, 16, and 18 by a multiplexed luminex assay. Clin Diagn Lab Immunol (2003) 3.76
In vitro generation and type-specific neutralization of a human papillomavirus type 16 virion pseudotype. J Virol (1996) 3.66
Assembly of herpes simplex virus (HSV) intermediate capsids in insect cells infected with recombinant baculoviruses expressing HSV capsid proteins. J Virol (1994) 3.24
Maturation of papillomavirus capsids. J Virol (2005) 3.18
Interaction of papillomaviruses with the cell surface. J Virol (1994) 2.44
Arrangement of L2 within the papillomavirus capsid. J Virol (2008) 2.37
Prophylactic human papillomavirus vaccines. J Clin Invest (2006) 2.36
Papillomavirus capsid protein expression level depends on the match between codon usage and tRNA availability. J Virol (1999) 2.35
Generation and neutralization of pseudovirions of human papillomavirus type 33. J Virol (1997) 2.29
Papillomavirus capsid binding and uptake by cells from different tissues and species. J Virol (1995) 2.24
How will HPV vaccines affect cervical cancer? Nat Rev Cancer (2006) 2.23
Human papillomavirus type 16 variant lineages in United States populations characterized by nucleotide sequence analysis of the E6, L2, and L1 coding segments. J Virol (1995) 2.13
The papillomavirus minor capsid protein, L2, induces localization of the major capsid protein, L1, and the viral transcription/replication protein, E2, to PML oncogenic domains. J Virol (1998) 2.12
Further evidence that papillomavirus capsids exist in two distinct conformations. J Virol (2003) 2.02
Assessment of the serological relatedness of genital human papillomaviruses by hemagglutination inhibition. J Virol (1996) 1.94
Interaction of human papillomavirus (HPV) type 16 capsid proteins with HPV DNA requires an intact L2 N-terminal sequence. J Virol (1994) 1.83
Characterization of late gene transcripts expressed during vegetative replication of human papillomavirus type 31b. J Virol (1997) 1.82
Three-dimensional structure of vaccinia virus-produced human papillomavirus type 1 capsids. J Virol (1994) 1.70
Binding and internalization of human papillomavirus type 33 virus-like particles by eukaryotic cells. J Virol (1995) 1.70
Quantitative disassembly and reassembly of human papillomavirus type 11 viruslike particles in vitro. J Virol (1998) 1.67
Immunization with viruslike particles induces long-term protection of rabbits against challenge with cottontail rabbit papillomavirus. J Virol (1996) 1.66
Understanding and learning from the success of prophylactic human papillomavirus vaccines. Nat Rev Microbiol (2012) 1.58
Expression of the human papillomavirus type 11 L1 capsid protein in Escherichia coli: characterization of protein domains involved in DNA binding and capsid assembly. J Virol (1997) 1.58
Human papillomavirus and HPV vaccines: a review. Bull World Health Organ (2007) 1.55
Immunization with a pentameric L1 fusion protein protects against papillomavirus infection. J Virol (2001) 1.55
Papillomavirus assembly requires trimerization of the major capsid protein by disulfides between two highly conserved cysteines. J Virol (1998) 1.52
Human papillomavirus type 11 recombinant L1 capsomeres induce virus-neutralizing antibodies. J Virol (1998) 1.49
Nasal immunization of mice with human papillomavirus type 16 virus-like particles elicits neutralizing antibodies in mucosal secretions. J Virol (1998) 1.48
Conserved features in papillomavirus and polyomavirus capsids. J Mol Biol (1996) 1.47
Human papillomavirus type 31b infection of human keratinocytes does not require heparan sulfate. J Virol (2005) 1.44
Human papillomavirus type 16 minor capsid protein l2 N-terminal region containing a common neutralization epitope binds to the cell surface and enters the cytoplasm. J Virol (2001) 1.44
The binding of histone deacetylases and the integrity of zinc finger-like motifs of the E7 protein are essential for the life cycle of human papillomavirus type 31. J Virol (2004) 1.43
Interactions between papillomavirus L1 and L2 capsid proteins. J Virol (2003) 1.41
Human papillomavirus type 16 virus-like particles expressed in attenuated Salmonella typhimurium elicit mucosal and systemic neutralizing antibodies in mice. Infect Immun (1997) 1.38
Prevalence of antibodies to human papillomavirus (HPV) type 16 virus-like particles in relation to cervical HPV infection among college women. Clin Diagn Lab Immunol (1997) 1.34
Two amino acid residues confer type specificity to a neutralizing, conformationally dependent epitope on human papillomavirus type 11. J Virol (1996) 1.29
DNA-induced structural changes in the papillomavirus capsid. J Virol (2001) 1.29
Identification of a human papillomavirus type 16-specific epitope on the C-terminal arm of the major capsid protein L1. J Virol (2003) 1.27
The L1 major capsid protein of human papillomavirus type 16 variants affects yield of virus-like particles produced in an insect cell expression system. J Clin Microbiol (1998) 1.25
Enhanced enzyme-linked immunosorbent assay for detection of antibodies to virus-like particles of human papillomavirus. J Clin Microbiol (2002) 1.22
In vitro infection and type-restricted antibody-mediated neutralization of authentic human papillomavirus type 16. J Virol (1998) 1.20
Identification of human papillomavirus type 16 L1 surface loops required for neutralization by human sera. J Virol (2006) 1.20
A neutralizing epitope of human papillomavirus type 11 is principally described by a continuous set of residues which overlap a distinct linear, surface-exposed epitope. J Virol (1997) 1.20
Replication and assembly of human papillomaviruses. J Dent Res (2009) 1.20
The evolving field of human papillomavirus receptor research: a review of binding and entry. J Virol (2013) 1.20
Immunotherapy for cervical cancer: Research status and clinical potential. BioDrugs (2010) 1.18
Production of human papillomavirus type 16 virus-like particles in transgenic plants. J Virol (2003) 1.15
Structural basis of oligosaccharide receptor recognition by human papillomavirus. J Biol Chem (2010) 1.13
Priming of human papillomavirus type 11-specific humoral and cellular immune responses in college-aged women with a virus-like particle vaccine. J Virol (2002) 1.08
Nuclear localization but not PML protein is required for incorporation of the papillomavirus minor capsid protein L2 into virus-like particles. J Virol (2004) 1.08
Human papillomavirus virus-like particles are efficient oral immunogens when coadministered with Escherichia coli heat-labile enterotoxin mutant R192G or CpG DNA. J Virol (2001) 1.02
Humoral immune response recognizes a complex set of epitopes on human papillomavirus type 6 l1 capsomers. J Virol (2005) 0.98
Mucosal delivery of human papillomavirus pseudovirus-encapsidated plasmids improves the potency of DNA vaccination. Mucosal Immunol (2010) 0.98
Maturation of the human papillomavirus 16 capsid. MBio (2014) 0.97
Efficacy of RG1-VLP vaccination against infections with genital and cutaneous human papillomaviruses. J Invest Dermatol (2013) 0.97
Characterization of neutralizing epitopes within the major capsid protein of human papillomavirus type 33. Virol J (2006) 0.95
Human papillomavirus-specific antibody status in oral fluids modestly reflects serum status in human immunodeficiency virus-positive individuals. Clin Diagn Lab Immunol (2003) 0.95
Characterization of virus-like particles in GARDASIL® by cryo transmission electron microscopy. Hum Vaccin Immunother (2013) 0.94
Structure-based engineering of papillomavirus major capsid l1: controlling particle assembly. Virol J (2007) 0.92
Cervarix: a vaccine for the prevention of HPV 16, 18-associated cervical cancer. Biologics (2008) 0.92
Host-cell factors involved in papillomavirus entry. Med Microbiol Immunol (2012) 0.92
Detection of neutralizing antibodies against human papillomaviruses (HPV) by inhibition of gene transfer mediated by HPV pseudovirions. J Clin Microbiol (2002) 0.91
Expression and characterization of HPV-16 L1 capsid protein in Pichia pastoris. Arch Virol (2009) 0.89
A cryo-electron microscopy study identifies the complete H16.V5 epitope and reveals global conformational changes initiated by binding of the neutralizing antibody fragment. J Virol (2014) 0.88
Second-generation prophylactic HPV vaccines: successes and challenges. Expert Rev Vaccines (2013) 0.88
A Virus-based Vaccine May Prevent Cervical Cancer. Curr Infect Dis Rep (2005) 0.88
Polymer-based enzyme-linked immunosorbent assay using human papillomavirus type 16 (HPV16) virus-like particles detects HPV16 clade-specific serologic responses. J Clin Microbiol (2003) 0.86
HPV in HIV-Infected Women: Implications for Primary Prevention. Front Oncol (2014) 0.86
Purification of recombinant budgerigar fledgling disease virus VP1 capsid protein and its ability for in vitro capsid assembly. J Virol (1994) 0.84
Mothers' human papilloma virus knowledge and willingness to vaccinate their adolescent daughters in Lagos, Nigeria. Int J Womens Health (2013) 0.84
Reducing the health burden of HPV infection through vaccination. Infect Dis Obstet Gynecol (2006) 0.83
A chimeric 18L1-45RG1 virus-like particle vaccine cross-protects against oncogenic alpha-7 human papillomavirus types. PLoS One (2015) 0.81
Papillomavirus capsid proteins mutually impact structure. Virology (2011) 0.81
Self-assembly of in vitro-translated human papillomavirus type 16 L1 capsid protein into virus-like particles and antigenic reactivity of the protein. Clin Diagn Lab Immunol (1996) 0.79
Serological responses to human papillomavirus type 6 and 16 virus-like particles in patients with cervical neoplastic lesions. Clin Diagn Lab Immunol (1996) 0.78
The role of vaccines in the control of STDs: HPV vaccines. Genitourin Med (1996) 0.77
A prime/boost strategy using DNA/fowlpox recombinants expressing the genetically attenuated E6 protein as a putative vaccine against HPV-16-associated cancers. J Transl Med (2015) 0.77
Papillomavirus Infectious Pathways: A Comparison of Systems. Viruses (2015) 0.77
Developments in L2-based human papillomavirus (HPV) vaccines. Virus Res (2016) 0.76
A human monoclonal antibody against HPV16 recognizes an immunodominant and neutralizing epitope partially overlapping with that of H16.V5. Sci Rep (2016) 0.76
Safety and immunogenicity of BPV-1 L1 virus-like particles in a dose-escalation vaccination trial in horses. Equine Vet J (2011) 0.75
Predicting the nuclear localization signals of 107 types of HPV L1 proteins by bioinformatic analysis. Genomics Proteomics Bioinformatics (2006) 0.75
Identification and validation of immunogenic potential of India specific HPV-16 variant constructs: In-silico &in-vivo insight to vaccine development. Sci Rep (2015) 0.75
Naturally occurring capsid protein variants L1 of human papillomavirus genotype 16 in Morocco. Bioinformation (2017) 0.75
General method for production and selection of infectious vaccinia virus recombinants expressing foreign genes. J Virol (1984) 10.98
High-expression vectors with multiple cloning sites for construction of trpE fusion genes: pATH vectors. Methods Enzymol (1991) 6.25
Structure of simian virus 40 at 3.8-A resolution. Nature (1991) 5.96
Human papillomaviruses in the pathogenesis of anogenital cancer. Virology (1991) 5.74
Polyoma virus capsid structure at 22.5 A resolution. Nature (1982) 4.19
Structures of bovine and human papillomaviruses. Analysis by cryoelectron microscopy and three-dimensional image reconstruction. Biophys J (1991) 4.07
Self-assembly of purified polyomavirus capsid protein VP1. Cell (1986) 4.00
Epidemiology of genital human papillomavirus infection. Epidemiol Rev (1988) 3.32
Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles. Virology (1991) 3.28
Reconstruction of the three-dimensional structure of simian virus 40 and visualization of the chromatin core. Proc Natl Acad Sci U S A (1988) 3.09
Characterization of a new type of human papillomavirus that causes skin warts. J Virol (1977) 2.94
Production of human papillomavirus and modulation of the infectious program in epithelial raft cultures. OFF. Genes Dev (1992) 2.90
Structural polypeptides of rabbit, bovine, and human papillomaviruses. J Virol (1975) 2.83
Comparative analysis of the human type 1a and bovine type 1 papillomavirus genomes. J Virol (1983) 2.69
The structure of viruses of the papilloma-polyoma type 3. Structure of rabbit papilloma virus, with an appendix on the topography of contrast in negative-staining for electron-microscopy. J Mol Biol (1965) 2.65
Retinoids as important regulators of terminal differentiation: examining keratin expression in individual epidermal cells at various stages of keratinization. J Cell Biol (1987) 2.62
Human immunodeficiency virus-like, nonreplicating, gag-env particles assemble in a recombinant vaccinia virus expression system. J Virol (1990) 2.58
Stratification and terminal differentiation of cultured epidermal cells. Nature (1982) 2.44
Laboratory production in vivo of infectious human papillomavirus type 11. J Virol (1987) 2.20
Inside polyomavirus at 25-A resolution. Nature (1992) 2.04
Identification of proteins encoded by the L1 and L2 open reading frames of human papillomavirus 1a. J Virol (1987) 2.01
The capsid of small papova viruses contains 72 pentameric capsomeres: direct evidence from cryo-electron-microscopy of simian virus 40. Biophys J (1989) 1.90
New vaccinia virus recombination plasmids incorporating a synthetic late promoter for high level expression of foreign proteins. Nucleic Acids Res (1990) 1.58
Identification of immunoreactive antigens of human papillomavirus type 6b by using Escherichia coli-expressed fusion proteins. J Virol (1988) 1.51
Reconstruction of 'simplified' skin: control of fabrication. Br J Dermatol (1984) 1.48
Human papillomaviruses and carcinomas. Adv Virus Res (1989) 1.46
The L2 open reading frame of human papillomavirus type 1a encodes a minor structural protein carrying type-specific antigens. J Virol (1986) 1.41
Processing, assembly, and immunogenicity of human immunodeficiency virus core antigens expressed by recombinant vaccinia virus. Virology (1990) 1.31
Identification of the nuclear localization signal of human papillomavirus type 16 L1 protein. Virology (1991) 1.21
Human antibodies react with an epitope of the human papillomavirus type 6b L1 open reading frame which is distinct from the type-common epitope. J Virol (1989) 1.20
Vaccinia: virus, vector, vaccine. Adv Virus Res (1988) 1.19
Detection of human papillomavirus capsid antigens in various squamous epithelial lesions using antibodies directed against the L1 and L2 open reading frames. Virology (1988) 1.12
Experimental infection with human papillomavirus type 1 of human hand and foot skin. Virology (1990) 1.07
Expression of the human papillomavirus type 6b L2 open reading frame in Escherichia coli: L2-beta-galactosidase fusion proteins and their antigenic properties. Virology (1987) 1.04
The hepatitis A virus polyprotein expressed by a recombinant vaccinia virus undergoes proteolytic processing and assembly into viruslike particles. J Virol (1991) 1.00
Characterization of murine polyclonal antisera and monoclonal antibodies generated against intact and denatured human papillomavirus type 1 virions. J Virol (1991) 0.96
Expression of human papillomavirus types 6b and 16 L1 open reading frames in Escherichia coli: detection of a 56,000-dalton polypeptide containing genus-specific (common) antigens. J Virol (1987) 0.92
Both Rb/p16INK4a inactivation and telomerase activity are required to immortalize human epithelial cells. Nature (1998) 7.81
A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection. N Engl J Med (1992) 5.96
Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis. Nat Med (1996) 4.51
Oral cancer risk in relation to sexual history and evidence of human papillomavirus infection. J Natl Cancer Inst (1998) 4.42
Long-term culture and immortalization of epithelial cells from normal adult human pancreatic ducts transfected by the E6E7 gene of human papilloma virus 16. Am J Pathol (1996) 4.25
The E7 gene of human papillomavirus type 16 is sufficient for immortalization of human epithelial cells. J Virol (1991) 4.18
Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection. J Infect Dis (2000) 3.36
Epidemiology of genital human papillomavirus infection. Epidemiol Rev (1988) 3.32
Surface conformational and linear epitopes on HPV-16 and HPV-18 L1 virus-like particles as defined by monoclonal antibodies. Virology (1996) 2.83
Inhibition of CDK activity and PCNA-dependent DNA replication by p21 is blocked by interaction with the HPV-16 E7 oncoprotein. Genes Dev (1997) 2.65
Inactivation of p16 in human mammary epithelial cells by CpG island methylation. Mol Cell Biol (1998) 2.64
The E6 and E7 genes of human papillomavirus type 6 have weak immortalizing activity in human epithelial cells. J Virol (1992) 2.61
The oncogenic potential of herpes simplex viruses: evidence for a 'hit-and-run' mechanism. Nature (1983) 2.26
Detection of herpes simplex RNA in human sensory ganglia. Virology (1979) 2.23
The natural history of human papillomavirus type 16 capsid antibodies among a cohort of university women. J Infect Dis (1996) 2.21
Human papillomavirus and prognosis of invasive cervical cancer: a population-based study. J Clin Oncol (2001) 2.18
Limited transcription of the herpes simplex virus genome when latent in human sensory ganglia. J Virol (1982) 2.12
Genomic variation of human papillomavirus type 16 and risk for high grade cervical intraepithelial neoplasia. J Natl Cancer Inst (1997) 2.06
Growth arrest by induction of p53 in DNA damaged keratinocytes is bypassed by human papillomavirus 16 E7. Proc Natl Acad Sci U S A (1994) 2.02
The ability of human papillomavirus E6 proteins to target p53 for degradation in vivo correlates with their ability to abrogate actinomycin D-induced growth arrest. J Virol (1994) 1.97
Inactivation of p53 enhances sensitivity to multiple chemotherapeutic agents. Cancer Res (1996) 1.93
Human papillomavirus 16 and 18 L1 serology compared across anogenital cancer sites. Cancer Res (2001) 1.89
Transformation of NIH 3T3 cells with cloned fragments of human cytomegalovirus strain AD169. J Virol (1982) 1.88
Low risk of perinatal transmission of human papillomavirus: results from a prospective cohort study. Am J Obstet Gynecol (1998) 1.84
Genital human papillomavirus infection in women who have sex with women. J Infect Dis (1998) 1.77
Evidence of prevalent genital-type human papillomavirus infections in adults and children. J Infect Dis (1990) 1.74
Cofactors with human papillomavirus in a population-based study of vulvar cancer. J Natl Cancer Inst (1997) 1.72
Human papillomavirus type 16 E7 alleviates a proliferation block in early passage human mammary epithelial cells. Oncogene (1996) 1.71
Three-dimensional structure of vaccinia virus-produced human papillomavirus type 1 capsids. J Virol (1994) 1.70
Nucleotide sequence of the herpes simplex virus type 2 thymidine kinase gene. J Virol (1983) 1.70
Clear cell carcinoma of the ovary: a retrospective multicentre experience of 254 patients with complete surgical staging. Br J Cancer (2006) 1.67
Destabilization of the retinoblastoma tumor suppressor by human papillomavirus type 16 E7 is not sufficient to overcome cell cycle arrest in human keratinocytes. J Virol (2001) 1.66
Human parvovirus B19 nonstructural (NS1) protein induces apoptosis in erythroid lineage cells. J Virol (1998) 1.61
Characterization of the gene encoding herpes simplex virus type 2 glycoprotein C and comparison with the type 1 counterpart. J Virol (1985) 1.60
Abrogation of the G2 checkpoint results in differential radiosensitization of G1 checkpoint-deficient and G1 checkpoint-competent cells. Cancer Res (1995) 1.59
E box-dependent activation of telomerase by human papillomavirus type 16 E6 does not require induction of c-myc. J Virol (2001) 1.58
Abrogation of growth arrest signals by human papillomavirus type 16 E7 is mediated by sequences required for transformation. J Virol (1996) 1.57
Progressive region-specific de novo methylation of the p16 CpG island in primary human mammary epithelial cell strains during escape from M(0) growth arrest. Mol Cell Biol (1999) 1.56
Sequence and structural requirements of a herpes simplex viral DNA replication origin. Mol Cell Biol (1988) 1.55
Transformation of rodent cells by a cloned DNA fragment of herpes simplex virus type 2. J Virol (1981) 1.54
Identification of immunoreactive antigens of human papillomavirus type 6b by using Escherichia coli-expressed fusion proteins. J Virol (1988) 1.51
Phase III randomised controlled trial of neoadjuvant chemotherapy plus radical surgery vs radical surgery alone for stages IB2, IIA2, and IIB cervical cancer: a Japan Clinical Oncology Group trial (JCOG 0102). Br J Cancer (2013) 1.50
The E7 protein of human papillomavirus type 16 is phosphorylated by casein kinase II. New Biol (1989) 1.47
Laboratory infection with human parvovirus B19. J Infect (1991) 1.47
Cloning and characterization of oriL2, a large palindromic DNA replication origin of herpes simplex virus type 2. J Virol (1986) 1.44
Human parvovirus B19 induces cell cycle arrest at G(2) phase with accumulation of mitotic cyclins. J Virol (2001) 1.43
Identification of proteins encoded by a fragment of herpes simplex virus type 2 DNA that has transforming activity. J Virol (1982) 1.42
Herpes simplex virus specifies two subunits of ribonucleotide reductase encoded by 3'-coterminal transcripts. J Virol (1986) 1.39
Identification of the E5 open reading frame of human papillomavirus type 16. J Virol (1988) 1.38
Structure of the transforming region of human cytomegalovirus AD169. J Virol (1984) 1.35
Small fragments of herpesvirus DNA with transforming activity contain insertion sequence-like structures. Proc Natl Acad Sci U S A (1984) 1.34
Defective G2 checkpoint function in cells from individuals with familial cancer syndromes. Cancer Res (1995) 1.32
Prevalence of genital papillomavirus infection among women attending a college student health clinic or a sexually transmitted disease clinic. J Infect Dis (1989) 1.26
HPV-1 capsids expressed in vitro detect human serum antibodies associated with foot warts. Virology (1993) 1.25
Elevated wild-type p53 protein levels in human epithelial cell lines immortalized by the human papillomavirus type 16 E7 gene. Virology (1994) 1.24
Disruption of the G1/S transition in human papillomavirus type 16 E7-expressing human cells is associated with altered regulation of cyclin E. J Virol (1998) 1.24
Human antibodies react with an epitope of the human papillomavirus type 6b L1 open reading frame which is distinct from the type-common epitope. J Virol (1989) 1.20
The G(2) checkpoint is maintained by redundant pathways. Mol Cell Biol (1999) 1.18
Small cell carcinoma of the endometrium: report of three cases and literature review. Int J Gynecol Cancer (2004) 1.18
Induction of cytotoxic T lymphocytes specific for a syngeneic tumor expressing the E6 oncoprotein of human papillomavirus type 16. J Immunol (1992) 1.18
The relationship of human papillomavirus-related cervical tumors to cigarette smoking, oral contraceptive use, and prior herpes simplex virus type 2 infection. Cancer Epidemiol Biomarkers Prev (1996) 1.17
Cervical carcinoma: detection of herpes simplex virus RNA in cells undergoing neoplastic change. Int J Cancer (1980) 1.16
Analysis of viral DNA sequences in hamster cells transformed by herpes simplex virus type 2. Proc Natl Acad Sci U S A (1980) 1.16
Cloning of Herpes simplex virus 2 DNA fragments in a plasmid vector. Gene (1980) 1.16
Organization of the left-hand end of the herpes simplex virus type 2 BglII N fragment. J Virol (1984) 1.15
Human papillomavirus and long-term oral contraceptive use increase the risk of adenocarcinoma in situ of the cervix. Cancer Epidemiol Biomarkers Prev (2001) 1.14
Analysis of human papillomavirus type 16 variants indicates establishment of persistent infection. J Infect Dis (1995) 1.14
Detection of human papillomavirus capsid antigens in various squamous epithelial lesions using antibodies directed against the L1 and L2 open reading frames. Virology (1988) 1.12
Location and cloning of the herpes simplex virus type 2 thymidine kinase gene. J Virol (1980) 1.11
Comparison of Southern transfer hybridization and dot filter hybridization for detection of cervical human papillomavirus infection with types 6, 11, 16, 18, 31, 33, and 35. Am J Clin Pathol (1990) 1.08
Predicted alpha-helix/beta-sheet secondary structures for the zinc-binding motifs of human papillomavirus E7 and E6 proteins by consensus prediction averaging and spectroscopic studies of E7. Biochem J (1996) 1.07
Low response rate of second-line chemotherapy for recurrent or refractory clear cell carcinoma of the ovary: a retrospective Japan Clear Cell Carcinoma Study. Int J Gynecol Cancer (2007) 1.03
Inactivation of G2 checkpoint function and chromosomal destabilization are linked in human fibroblasts expressing human papillomavirus type 16 E6. Cell Growth Differ (1997) 1.02
SRY mutation and tumor formation on the gonads of XP pure gonadal dysgenesis patients. Cancer Genet Cytogenet (1999) 1.01
Characterization of human antibody-reactive epitopes encoded by human papillomavirus types 16 and 18. J Virol (1991) 1.01
Generation of a human melanocyte cell line by introduction of HPV16 E6 and E7 genes. In Vitro Cell Dev Biol Anim (1997) 1.00
Expression of CD44 in normal human versus tumor endometrial tissues: possible implication of reduced expression of CD44 in lymph-vascular space involvement of cancer cells. Cancer Res (1994) 0.99
Seroprevalence of human papillomavirus types 6 and 16 capsid antibodies in homosexual men. J Infect Dis (1997) 0.98
HLA allelic variants encoding DR11 in diffuse and limited systemic sclerosis in Caucasian women. Rheumatology (Oxford) (2004) 0.98
Use of HPV 1 capsids produced by recombinant vaccinia viruses in an ELISA to detect serum antibodies in people with foot warts. Virology (1994) 0.98
Serologic evidence of herpes simplex virus 1 infection and oropharyngeal cancer risk. Cancer Res (2001) 0.96
Characterization of murine polyclonal antisera and monoclonal antibodies generated against intact and denatured human papillomavirus type 1 virions. J Virol (1991) 0.96
The E6 protein of human papillomavirus type 16 functions as a transcriptional repressor in a mechanism independent of the tumor suppressor protein, p53. Virology (1994) 0.96
p21CIP1 is not required for the early G2 checkpoint response to ionizing radiation. Cancer Res (1995) 0.95
Human antibodies recognize multiple distinct type-specific and cross-reactive regions of the minor capsid proteins of human papillomavirus types 6 and 11. J Virol (1992) 0.95
Risk of anal carcinoma in situ in relation to human papillomavirus type 16 variants. Cancer Res (1998) 0.93
Transformation of rat cells by the hybrid virus Ad2(2+) HEY. J Gen Virol (1979) 0.93
Comparative virologic studies of condylomata acuminata reveal a lack of dual infections with human papillomaviruses. J Infect Dis (1991) 0.93
Intraoperative electrical stimulation of the pelvic splanchnic nerves during nerve-sparing radical hysterectomy. Gynecol Oncol (2005) 0.92
Papillomavirus capsids: a new approach to identify serological markers of HPV infection. J Natl Cancer Inst (1994) 0.92
Paclitaxel-platinum combination chemotherapy for advanced or recurrent ovarian clear cell adenocarcinoma: a multicenter trial. Int J Gynecol Cancer (2006) 0.91
Metastatic conversion of cells by expression of human papillomavirus type 16 E6 and E7 genes. Proc Natl Acad Sci U S A (1993) 0.91
Expression of human papillomavirus proteins in yeast Saccharomyces cerevisiae. Virology (1991) 0.91
Inguinal endometriosis attaching to the round ligament. Australas Radiol (2007) 0.91
Yokukansan, a traditional Japanese medicine, ameliorates memory disturbance and abnormal social interaction with anti-aggregation effect of cerebral amyloid β proteins in amyloid precursor protein transgenic mice. Neuroscience (2011) 0.90
Detection of cervical antibodies to human papillomavirus type 16 (HPV-16) capsid antigens in relation to detection of HPV-16 DNA and cervical lesions. J Infect Dis (2000) 0.90
The p53 Arg72Pro polymorphism, human papillomavirus, and invasive squamous cell cervical cancer. Cancer Epidemiol Biomarkers Prev (2000) 0.90
Paget's disease of the vulva: clinicopathologic study of type 1 cases treated at a single institution. Int J Gynecol Cancer (2006) 0.89